Bruker Corporation Commissions Novel 18 Tesla MRI in Portugal
Bruker Corporation announced the commissioning of a novel BioSpec 18 Tesla preclinical MRI at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging and magnetic resonance spectroscopic imaging methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. Installed at the Champalimaud Foundation's preclinical MRI laboratory in Lisbon under the leadership of Professor Noam Shemesh, the BioSpec 18T supports advanced neuroscience and oncology research for in vivo studies of cancer, metastasis, brain plasticity and neural activity in preclinical models, while supporting the discovery of novel imaging biomarkers with translational relevance. The 18 Tesla system complements Champalimaud's existing 16.4 Tesla vertical-bore MRI/NMR and 9.4 Tesla horizontal-bore MRI.
